1-4 of 4
Boris V Afanasiev, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Reduced Intensity Vs. Standard Conditioning Followed By Allogeneic Stem Cell Transplantation for Patients with MDS or Secondary AML: A Prospective, Randomized Phase III Study of the Chronic Malignancies Working Party of the EBMT (RICMAC-Trial)

Nicolaus Kröger, MD, Ronald Brand, PhD, Dietger Niederwieser, MD, Uwe Platzbecker, MD, Kai Hübel, MD, Thomas Weber, MD, Marie Robin, MD PhD, Matthias Stelljes, MD, Boris V Afanasiev, MD, Dominik Heim, MD, Giorgio Lambertenghi Deliliers, MD, Francesco Onida, MD, Peter Dreger, MD, Massimo Pini, MD, Stefano Guidi, Liisa Volin, MD, Martin Gramatzki, MD, Wolfgang A. Bethge, MD, Xavier Poire, MD, Guido Kobbe, MD, Marleen van Os, Simona Iacobelli, Theo de Witte, MD
Journal: Blood
Blood (2014) 124 (21): 320.
https://doi.org/10.1182/blood.V124.21.320.320
Published: 2014
Journal Articles

Assessment of Minimal Residual Disease (MRD) In Relapsed CLL Patients Treated with Fludarabine and Cyclophosphamide with or without Rituximab (REACH)

Annika Dufour, MD, S. K Bohlander, PhD, Karsten Spiekermann, MD, Stephanie Schneider, Jan Braess, MD, Purvi Kakadiya, Kirsten E Mundt, PhD, Helen Smith, Ming Lin, PhD, Martin Barrett, PhD, Deborah Hurst, MD, Anna Dmoszynska, MD, PhD, Isabelle Bence-Bruckler, MD, FRCPC, Boris V Afanasiev, MD, John Catalano, MBBS, FRACP, FRCPA, Marco Montillo, Christian H. Geisler, MD, Sergey I Moiseev, MD, Philippe Solal-Celigny, MD, Tadeusz Robak, Wolfgang Hiddemann, MD
Journal: Blood
Blood (2010) 116 (21): 1390.
https://doi.org/10.1182/blood.V116.21.1390.1390
Published: 2010
Journal Articles

FC-Gamma Receptor (FCGR) 2A and 3A Polymorphisms Do Not Influence the Outcome of Relapsed or Refractory CLL Patients Treated with Rituximab, Fludarabine, and Cyclophosphamide (R-FC) or Fludarabine, and Cyclophosphamide (FC) Alone.

David Dornan, Ph.D, Olivia Spleiss, Ph.D, Ru-Fang T Yeh, PhD, Guillemette Duchateau-Nguyen, PhD, Tadeusz Robak, Sergey I Moiseev, MD, Anna Dmoszynska, MD, Philippe Solal-Celigny, MD, Krzysztof Warzocha, MD, PhD, Javier Loscertales, MD, John Catalano, MD, Boris V Afanasiev, MD, Loree Larratt, MD, Viktor A Rossiev, MD, PhD, Isabelle Bence-Bruckler, MD, FRCPC, Christian H. Geisler, MD, DMSc, Marco Montillo, MD, Michael K. Wenger, MD, Martin Weisser, MD
Journal: Blood
Blood (2009) 114 (22): 2338.
https://doi.org/10.1182/blood.V114.22.2338.2338
Published: 2009
Journal Articles

Rituximab, Fludarabine, and Cyclophosphamide (R-FC) Prolongs Progression Free Survival in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Compared with FC Alone: Final Results from the International Randomized Phase III REACH Trial

Tadeusz Robak, MD, PhD, Sergey I Moiseev, MD, Anna Dmoszynska, MD, Philippe Solal-Céligny, MD, Krzysztof Warzocha, MD, PhD, Javier Loscertales, MD, John Catalano, MD, Boris V Afanasiev, MD, Loree Larratt, MD, Christian Geisler, MD, DMSc, Marco Montillo, MD, Peter Ganly, BMBCh, PhD, Caroline Dartigeas, MD, András Rosta, MD, PhD, Ann Janssens, MD, Myriam Mendila, MD, Jörg Maurer, Michael K. Wenger, MD
Journal: Blood
Blood (2008) 112 (11): lba-1.
https://doi.org/10.1182/blood.V112.11.lba-1.lba-1
Published: 2008